Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.

Dinmohamed, A G; van Norden, Y; Visser, O; Posthuma, E F M; Huijgens, P C; Sonneveld, P; van de Loosdrecht, A A; Jongen-Lavrencic, M

Dinmohamed, A G; van Norden, Y; Visser, O; Posthuma, E F M; Huijgens, P C; Sonneveld, P; van de Loosdrecht, A A; Jongen-Lavrencic, M.

Afiliação

Dinmohamed AG; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
van Norden Y; Clinical Trial Center-HOVON Data Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Visser O; Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Posthuma EF; Department of Internal Medicine, Reinier de Graaf Group, Delft, The Netherlands.
Huijgens PC; Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Sonneveld P; Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
van de Loosdrecht AA; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jongen-Lavrencic M; Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.

Leukemia ; 29(12): 2449-51, 2015 Dec.

Article em En | MEDLINE | ID: mdl-26369829

Assuntos

Antimetabólitos Antineoplásicos/uso terapêutico; Azacitidina/uso terapêutico; Síndromes Mielodisplásicas/tratamento farmacológico; Feminino; Humanos; Masculino

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Azacitidina / Síndromes Mielodisplásicas / Antimetabólitos Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google